FDA Announces De Novo Classification Process for Automatic Class III Designation

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, as part of its de novo classification process for automatic Class III designation.